Recent Advances in Inflammation & Allergy Drug Discovery

Scope & Guideline

Exploring breakthroughs in inflammation and allergy science.

Introduction

Immerse yourself in the scholarly insights of Recent Advances in Inflammation & Allergy Drug Discovery with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2772-2708
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2021 to 2024
AbbreviationRECENT ADV INFLAMM A / Recent Adv. Inflamm. Allergy Drug Discov.
Frequency2 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

The journal 'Recent Advances in Inflammation & Allergy Drug Discovery' focuses on the multifaceted aspects of inflammation and allergy, emphasizing innovative approaches to drug discovery and therapeutic strategies. It serves as a platform for interdisciplinary research that explores both traditional and novel therapeutic modalities.
  1. Drug Discovery and Development:
    The journal primarily aims to publish research related to the discovery and development of new drugs targeting inflammatory and allergic conditions, integrating both pharmaceutical innovations and natural product research.
  2. Mechanistic Insights into Inflammation and Allergy:
    Research that delves into the biological mechanisms underlying inflammation and allergic responses is a core focus, helping to elucidate pathways that can be targeted for therapeutic intervention.
  3. Interdisciplinary Approaches:
    The journal encourages studies that incorporate various scientific disciplines, including pharmacology, immunology, biochemistry, and molecular biology, to foster a comprehensive understanding of inflammation and allergy.
  4. Therapeutic Innovations:
    A significant aim is to showcase innovative therapeutic strategies, including the use of nanotechnology, phytochemicals, and novel drug formulations, to enhance treatment efficacy and safety.
  5. Clinical Applications and Case Studies:
    The journal also emphasizes clinical research and case studies that provide insights into the practical application of new therapies, offering real-world implications for healthcare practitioners.
The journal has identified several emerging themes and trends that reflect the current landscape of research in inflammation and allergy. These areas are gaining traction among researchers and are likely to shape future studies.
  1. Phytochemicals and Natural Products:
    An increasing number of studies are exploring the therapeutic potential of bioactive phytochemicals and natural products, emphasizing their role in managing inflammation and allergic conditions.
  2. Nanotechnology in Drug Delivery:
    Research utilizing nanotechnology for drug formulation and targeted delivery is on the rise, showcasing innovative methods to enhance the efficacy and safety of anti-inflammatory therapies.
  3. Immunotherapy and Biologics:
    There is a growing focus on immunotherapeutic strategies and biologics, particularly in the context of allergy treatments, reflecting advancements in personalized medicine.
  4. Microbiome and Probiotics:
    Emerging research is highlighting the role of the microbiome and probiotic therapies in modulating immune responses and their potential in treating allergic diseases.
  5. Comprehensive Mechanistic Studies:
    There is an increasing trend towards detailed mechanistic studies that provide insights into the pathophysiology of inflammatory diseases, aiding in the identification of novel therapeutic targets.

Declining or Waning

While the journal continues to evolve, certain themes have shown a decline in frequency and relevance over recent years. This section highlights areas that may be waning in prominence within the journal's publications.
  1. Conventional Pharmacotherapy:
    There is a noticeable decrease in studies focusing exclusively on traditional pharmaceutical approaches without exploring alternative or integrative methodologies, indicating a shift towards more innovative treatment strategies.
  2. Case Reports and Limited Scope Studies:
    The frequency of case reports and studies with limited scope has diminished, suggesting a preference for more comprehensive and detailed investigations that address broader implications and therapeutic potentials.
  3. Basic Science without Clinical Relevance:
    Research that focuses solely on basic scientific principles without direct clinical applications has seen a decline, as the journal increasingly favors studies that bridge the gap between laboratory findings and clinical practice.
  4. Single-Target Therapeutics:
    There is a waning interest in studies that target single pathways or mechanisms in inflammation and allergy, as the trend shifts towards understanding complex interactions and multi-target approaches.
  5. Historical Reviews of Established Therapies:
    The journal has moved away from publishing extensive reviews of established therapies that lack new insights, focusing instead on emerging treatments and innovative research.

Similar Journals

Drug Target Insights

Connecting Researchers to Transformative Drug Insights.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

European Journal of Inflammation

Connecting researchers in the fight against inflammation.
Publisher: SAGE PUBLICATIONS INCISSN: 1721-727XFrequency: 1 issue/year

The European Journal of Inflammation, published by SAGE Publications Inc, is a dedicated platform for the dissemination of innovative research in the field of immunology and inflammation, with a strong commitment to advancing scientific knowledge in allergy and related disciplines. Established in 2004, this open access journal has been providing a crucial avenue for researchers, practitioners, and students to share findings and insights in an increasingly important area of health science, especially since transitioning to open access in 2017. With an ISSN of 1721-727X and an E-ISSN of 2058-7392, the journal has made significant strides, though currently holds a Q4 category ranking in the realms of Immunology and Allergy according to 2023 quartiles. The journal's visibility is further reflected in its Scopus ranks, positioned at #190 in Medicine (Immunology and Allergy) and #206 in Immunology and Microbiology (Immunology). Its scope encompasses a wide range of topics related to inflammation, making it a valuable resource for those engaged in cutting-edge research. With a rapidly evolving landscape in immunological research, the European Journal of Inflammation stands as an essential resource for anyone looking to stay informed and contribute to this vital area of medicine.

BIOMEDICINE & PHARMACOTHERAPY

Pioneering insights for better health outcomes.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0753-3322Frequency: 12 issues/year

BIOMEDICINE & PHARMACOTHERAPY is a distinguished journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, specializing in the essential fields of medicine and pharmacology. Established in 1982 and covering literature up to 2024, this journal is notably recognized for its impact, holding a prestigious Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, as well as a commendable position within the top 10% of its category based on Scopus rankings. Researchers and practitioners will find it serves as a vital resource for the latest advancements, innovations, and critical reviews in the life sciences and therapeutic practices. The journal emphasizes rigorous peer review and high-quality publications, aimed at facilitating knowledge dissemination in biomedicine and pharmacotherapy. Its commitment to excellence makes it an indispensable platform for contributors and readers alike who are engaged in improving health outcomes through pharmaceutical research and medical advances.

AIMS Allergy and Immunology

Empowering Global Collaboration in Immunological Research
Publisher: AMER INST MATHEMATICAL SCIENCES-AIMSISSN: 2575-615XFrequency: 4 issues/year

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

BIOMEDICAL RESEARCH-TOKYO

Exploring Pioneering Research in Biochemistry and Genetics
Publisher: BIOMEDICAL RESEARCH PRESS LTDISSN: 0388-6107Frequency: 6 issues/year

BIOMEDICAL RESEARCH-TOKYO is an esteemed interdisciplinary journal published by BIOMEDICAL RESEARCH PRESS LTD, dedicated to disseminating pioneering research and advancements in the fields of biochemistry, genetics, and medicine. Since its inception in 1980, the journal has established itself as a reputable source of knowledge, contributing significantly to the global scientific community with its strong emphasis on innovative findings and methodologies. With a consistent presence in the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it continues to attract a diverse range of research articles. While the journal does not operate as an open access platform, it remains an essential resource for researchers, professionals, and students seeking to further their understanding of biomedical sciences. Located in Sapporo, Japan, this journal fosters collaboration and knowledge sharing among the international biomedical research community, engaging readers through its compelling studies that span from 1980 to 2024.

Translational Research

Transforming Science into Health Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

International Journal of Inflammation

Leading the Charge in Immunological Discoveries
Publisher: HINDAWI LTDISSN: 2090-8040Frequency:

The International Journal of Inflammation, published by HINDAWI LTD, serves as a vital resource within the field of Immunology and Allergy. With an established Open Access policy since 2010, this journal provides unrestricted access to cutting-edge research, fostering collaboration and dissemination of knowledge among researchers, professionals, and students. The journal’s ISSN is 2090-8040 and E-ISSN 2042-0099. Situated in the United States with administrative offices in England, it has consistently contributed to the academic community, evidenced by its ranking in the Q3 category for 2023, reflecting its significant presence in the field. Covering a wide range of topics from the molecular basis of inflammation to clinical implications and treatment strategies, the journal engages with the latest developments and current debates. With a Scopus rank of 145 out of 233 in the category of Medicine, its percentile rank of 37th indicates its influence and relevance in contemporary research. As the journal continues to evolve from its convergence years spanning from 2012 to 2024, it remains committed to advancing knowledge and innovation in inflammation research.

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Empowering Researchers with Concise Reviews of Cutting-edge Science.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-5575Frequency: 20 issues/year

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

Science Translational Medicine

Driving Medical Advancements Through Research.
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: 1946-6234Frequency: 51 issues/year

Science Translational Medicine is a premier journal published by the American Association for the Advancement of Science, dedicated to bridging the gap between laboratory discovery and clinical application. With an impressive impact factor and a Q1 categorization in the field of Medicine, it is recognized as one of the leading journals, ranking 11 out of 636 in general medicine according to Scopus, placing it in the top 2% of its category. Since its inception in 2009, the journal has been at the forefront of innovative research, presenting high-quality studies that translate scientific advancements into tangible medical solutions. Researchers, professionals, and students alike will find its rich content invaluable for staying informed on cutting-edge developments in the field. The journal's commitment to accessibility ensures that the latest findings and insights are available to a global audience, fostering collaboration and scientific progress.

ARCHIVES OF PHARMACAL RESEARCH

Exploring the frontiers of pharmacal science for a healthier future.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.